Mikael Dolsten

Mikael Dolsten is the founder of Quarry Thera LLC, founded in 2024, serving as Director.
Current jobs include Chairman at Orbis Medicines ApS; Independent Director at Agilent Technologies, Inc. since 2021; Director at Research!America, PhRMA Foundation, Arbor Biotechnologies, Inc., Chai Discovery, Inc., and Rocket Pharmaceuticals, Inc. since 2024; Independent Director at Swedish Orphan Biovitrum AB starting 2026; Member-Overseers Board at The Scripps Research Institute; Member-Governors Board at New York Academy of Sciences; Member at Royal Swedish Academy of Engineering Sciences; and Member at Government-University-Industry Research Roundtable.
Former jobs include Independent Director at Vimian Group AB (2021–2025), Karyopharm Therapeutics, Inc. (2015–2021), and Apellis Pharmaceuticals, Inc. (2026);.
Senior Vice President at Wyeth LLC (2008–2009); Global Vice President at AstraZeneca PLC; Principal at OrbiMed Advisors LLC (2008); Senior Vice President at Wyeth Pharmaceuticals LLC (2008–2009); Executive VP & Head-Worldwide Research at Boehringer Ingelheim Pharmaceuticals, Inc. (2003–2008); Trustee at New York Hall of Science; President at Wyeth Research (2008–2009); Partner at OrbiMed Advisors Private Equity (2008); and Co-Chief Scientific Officer & President-Research at Pfizer Inc. (2009–2025).
Education includes a doctorate from the University of Lund.